Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma

NCT03295227 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03295227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03295227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
December 6, 2017
Completion date
December 31, 2027
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii thymoma ajcc v8, stage iiia thymoma ajcc v8, stage iiib thymoma ajcc v8, stage iv thymoma ajcc v8, stage iva thymoma ajcc v8, stage ivb thymoma ajcc v8, unresectable thymic carcinoma